Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
- Status
- WITHDRAWN
- Phase
- PHASE2
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- Status
- TERMINATED
- Phase
- PHASE3
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
- Status
- TERMINATED
- Phase
- PHASE2